Examinations of Dupilumab Efficacy Across Various Patient Types and Anatomic Areas in the Management of Atopic Dermatitis

Benjamin Lockshin, MD, FAAD, comments on the significance of recent expansions of therapeutics options for patients with atopic dermatitis and unmet needs in the field.

Benjamin Lockshin, MD, FAAD, reviews key findings from a phase 2 trial evaluating the safety and efficacy of single-dose dupilumab in children with severe atopic dermatitis.

An expert dermatologist evaluates the role of dupilumab in decreasing the clinical burden of severe atopic dermatitis on patients and their caregivers and shares insight on the future outlook of dupilumab in disease management.

Andrew Blauvelt, MD, MBA, reviews recent advances in the therapeutic landscape for moderate to severe atopic dermatitis.

Dr Andrew Blauvelt reviews key highlights and clinical implications from the LIBERTY AD OLE study assessing the effect of long-term dupilumab treatment on efficacy improvements in adults with moderate to severe atopic dermatitis.

An expert dermatologist provides key takeaways and the real-world significance of dupilumab use for the treatment of atopic dermatitis.

Andrew Blauvelt, MD, MBA, reviews clinical implications from the phase 3 LIBERTY AD CHRONOS study examining the efficacy of dupilumab plus topical corticosteroids in adult patients with moderate to severe atopic dermatitis.

Dr Andrew Blauvelt discusses the relevance of dupilumab treatment response as seen in the LIBERTY AD OLE and LIBERTY AD CHRONOS studies and shares his approaches to improving atopic dermatitis management.

An expert dermatologist provides insight on unmet needs in clinical trial endpoint measurements that would improve the management of atopic dermatitis.

Andrew Blauvelt, MD, MBA, shares clinical pearls for the management of atopic dermatitis with systemic therapy.